 ft 01 jun 92 market prescript wellcom john robb talk prospect drug group  wellcom chief execut mr john robb pride market orient approach busi 56 year scot consum product execut beecham prove determin make group market driven appoint chairman sir alistair frame juli 1990 mr robb face biggest market challeng life sale 50 cent group largest issu privat own british compani offer schedul mid juli rais pound 4bn view task difficult compani fastest grow world 20 largest pharmaceut compani year averag wellcom enjoy highest earn share growth rate pharmaceut stock 30 3 cent compar 17 6 cent glaxo 15 7 cent smithklin beecham addit compani domin posit 80 cent fast grow anti viral market sale zovirax herp treatment expect grow 20 cent year reach pound 820m 1994 retrovir anti aid drug azt reach annual sale pound 340m 1994 recent note sg warburg compani broker wellcom short term futur bright mr robb task complic doubt long term growth benefici effect group wide rang dispos programm run year helm oper margin improv 21 2 cent 1990 24 6 cent year half year rose 2 5 percentag point 26 7 cent half improv programm dispos come end threat end patent zovirax half 1992 sale increas 26 cent comment 40 cent wellcom revenu growth product year main patent expir germani year uk 1995 japan 1997 sale grow remark fast launch mr robb recognis threat zovirax develop twin strategi deal problem element consist compound 256u 882c eventu replac zovirax drug launch 1995 1996 clinic trial time crucial smithklin beecham mr robb acknowledg excel market track record schedul launch competitor drug famciclovir 1995 element mr robb defenc strategi sell zovirax doctor prescript chemist don market clout exploit zovirax otc counter market admit mr robb partner europ left short list play threat retrovir wellcom anti aid drug argu analyst stage fixat retrovir group relat aid drug repres 11 cent group turnov year competit retrovir drug make impact medium term reckon mr robb view aid continu treat retrovir combin therapi year market grow competit nois moment concern exist challeng retrovir patent patent valid challeng barr laboratori group outcom case unclear decid year juri north carolina wellcom lose plan appeal barr market generic version drug spite problem face group mr robb confid deliv target promis includ under sale growth excess 10 cent oper margin 30 cent 1996 earn share growth 15 cent year group research develop focus compani remain commit outstand research adopt project manag approach perfect glaxo 1980s involv drop compound fail reach develop target time septemb 1989 number compound develop fallen 78 34 drug fulli develop launch market justifi money invest cost dollar 230m pound 127m bring drug market market terribl import great reput research develop compar reput market research develop product sell plan improv market expand wellcom sale forc hire sale manag japan continu strategi market compani incred import rais market skill level research develop skill mr robb don ll troubl launch world wide market campaign thursday challeng make flotat run troubl pound 4bn stake vaunt market skill demand 